Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A setting...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-01-01
|
| Series: | Molecular Therapy: Methods & Clinical Development |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050116301462 |
| _version_ | 1828236490350526464 |
|---|---|
| author | Allison M Lytle Harrison C Brown Na Yoon Paik Kristopher A Knight J Fraser Wright H Trent Spencer Christopher B Doering |
| author_facet | Allison M Lytle Harrison C Brown Na Yoon Paik Kristopher A Knight J Fraser Wright H Trent Spencer Christopher B Doering |
| author_sort | Allison M Lytle |
| collection | DOAJ |
| description | Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A settings. Liver-directed adeno-associated viral (AAV)-FIX vector gene transfer achieved similar results in preclinical hemophilia B models. However, as clinical immune responses to FVIII and FIX differ, we investigated the ability of liver-directed AAV-FVIII gene therapy to affect FVIII immunity in hemophilia A mice. Both FVIII naive and preimmunized mice were administered recombinant AAV8 encoding a liver-directed bioengineered FVIII expression cassette. Naive animals receiving high or mid-doses subsequently achieved near normal FVIII activity levels. However, challenge with adjuvant-free recombinant FVIII induced loss of FVIII activity and anti-FVIII antibodies in mid-dose, but not high-dose AAV or HSC lentiviral (LV) vector gene therapy cohorts. Furthermore, unlike what was shown previously for FIX gene transfer, AAV-FVIII administration to hemophilia A inhibitor mice conferred no effect on anti-FVIII antibody or inhibitory titers. These data suggest that functional differences exist in the immune modulation achieved to FVIII or FIX in hemophilia mice by gene therapy approaches incorporating liver-directed AAV vectors or HSC-directed LV. |
| first_indexed | 2024-04-12T20:33:00Z |
| format | Article |
| id | doaj.art-8d2ed94f878744bcbf391d34f101c04b |
| institution | Directory Open Access Journal |
| issn | 2329-0501 |
| language | English |
| last_indexed | 2024-04-12T20:33:00Z |
| publishDate | 2016-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Methods & Clinical Development |
| spelling | doaj.art-8d2ed94f878744bcbf391d34f101c04b2022-12-22T03:17:40ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012016-01-013C10.1038/mtm.2015.56Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia AAllison M Lytle0Harrison C Brown1Na Yoon Paik2Kristopher A Knight3J Fraser Wright4H Trent Spencer5Christopher B Doering6Graduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, USAGraduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, USAAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USAAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USADepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USAAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USAImmune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A settings. Liver-directed adeno-associated viral (AAV)-FIX vector gene transfer achieved similar results in preclinical hemophilia B models. However, as clinical immune responses to FVIII and FIX differ, we investigated the ability of liver-directed AAV-FVIII gene therapy to affect FVIII immunity in hemophilia A mice. Both FVIII naive and preimmunized mice were administered recombinant AAV8 encoding a liver-directed bioengineered FVIII expression cassette. Naive animals receiving high or mid-doses subsequently achieved near normal FVIII activity levels. However, challenge with adjuvant-free recombinant FVIII induced loss of FVIII activity and anti-FVIII antibodies in mid-dose, but not high-dose AAV or HSC lentiviral (LV) vector gene therapy cohorts. Furthermore, unlike what was shown previously for FIX gene transfer, AAV-FVIII administration to hemophilia A inhibitor mice conferred no effect on anti-FVIII antibody or inhibitory titers. These data suggest that functional differences exist in the immune modulation achieved to FVIII or FIX in hemophilia mice by gene therapy approaches incorporating liver-directed AAV vectors or HSC-directed LV.http://www.sciencedirect.com/science/article/pii/S2329050116301462 |
| spellingShingle | Allison M Lytle Harrison C Brown Na Yoon Paik Kristopher A Knight J Fraser Wright H Trent Spencer Christopher B Doering Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A Molecular Therapy: Methods & Clinical Development |
| title | Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A |
| title_full | Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A |
| title_fullStr | Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A |
| title_full_unstemmed | Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A |
| title_short | Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A |
| title_sort | effects of fviii immunity on hepatocyte and hematopoietic stem cell directed gene therapy of murine hemophilia a |
| url | http://www.sciencedirect.com/science/article/pii/S2329050116301462 |
| work_keys_str_mv | AT allisonmlytle effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT harrisoncbrown effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT nayoonpaik effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT kristopheraknight effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT jfraserwright effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT htrentspencer effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa AT christopherbdoering effectsoffviiiimmunityonhepatocyteandhematopoieticstemcelldirectedgenetherapyofmurinehemophiliaa |